Gilead Sciences, Inc.
NASDAQ:GILDDrug Manufacturers - General
-$2.69 today
- Market cap
- $209.59B
- Beta
- 0.33
- P/E (TTM)
- 16.5
- EPS (TTM)
- $7.42
- Dividend yield
- 2.62%
Volume 4.82M
Average 6.78M
GILD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Gilead Sciences, Inc.NASDAQ: GILD
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns negative
Q2 FY2026 EBITDA was -$9.31B, compared with $3.37B a year earlier. Trailing-twelve-month EBITDA was $1.33B. Over 3 fiscal years it compounded at +15.3% a year.
Context
- EBITDA amounted to 46.1% of revenue in FY2025, up 30.7 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 18 analysts of $2.08B (-84.7%) for the fiscal year ending Dec 2026, a slowdown from the +206.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$9.31B-406.2% QoQ
- Last fiscal yearDec 2025
- $13.58B+206.3% YoY
- LTMJun 2026
- $1.33B-87.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -375.9% | -1.9% | +374.0 pp |
| 1 year | +206.3% | -84.7% | -290.9 pp |
| 3-year CAGR | +15.3% | +13.4% | -1.9 pp |
| 5-year CAGR | +11.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 13.58B USD
- Year-over-year change
- +206.3%
- 4-year CAGR
- +4.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.58B | +206.3% |
| FY2024 | 2024-12-31 | 4.43B | -57.8% |
| FY2023 | 2023-12-31 | 10.5B | +18.6% |
| FY2022 | 2022-12-31 | 8.85B | -21.9% |
| FY2021 | 2021-12-31 | 11.33B | — |
EBITDA vs competitors
How GILD compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -87.8% is the lowest of 10, against a peer median of +2.2%.
- EBITDA amounts to 4.4% of revenue for GILD, versus a peer median of 31.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding GILD) | — | +2.2% | +9.9% | 31.0% | |
Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 27.31B | 27.28B | 27.12B | 28.75B | 29.44B |
| Cost of Revenue | 6.6B | 5.66B | 6.5B | 6.25B | 6.23B |
| Gross Profit | 20.7B | 21.62B | 20.62B | 22.5B | 23.21B |
| Gross Margin | 75.8% | 79.3% | 76.0% | 78.3% | 78.8% |
| Research & Development | 4.6B | 4.98B | 5.72B | 5.91B | 5.8B |
| Selling, General & Admin | 5.25B | 5.67B | 6.09B | 6.09B | 5.71B |
| Operating Expenses | 10.79B | 14.29B | 13.01B | 20.84B | 11.51B |
| Depreciation & Amortization | 2.05B | 2.1B | 2.69B | 2.77B | 2.76B |
| EBITDA | 11.33B | 8.85B | 10.5B | 4.43B | 13.58B |
| EBITDA Margin | 41.5% | 32.4% | 38.7% | 15.4% | 46.1% |
| Operating Income | 9.92B | 7.33B | 7.61B | 1.66B | 11.7B |
| Operating Margin | 36.3% | 26.9% | 28.0% | 5.8% | 39.7% |
| Interest Income | 0 | 106M | 376M | 281M | 349M |
| Interest Expense | 1B | 935M | 944M | 977M | 1.02B |
| Other Income / Expenses | (1.64B) | (1.52B) | (746M) | (972M) | (1.91B) |
| Income Before Tax | 8.28B | 5.81B | 6.86B | 690M | 9.8B |
| Pre-Tax Margin | 30.3% | 21.3% | 25.3% | 2.4% | 33.3% |
| Income Tax Expense | 2.08B | 1.25B | 1.25B | 211M | 1.29B |
| Net Income | 6.23B | 4.59B | 5.67B | 480M | 8.51B |
| Net Margin | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| EPS (Basic) | 4.96 | 3.66 | 4.54 | 0.38 | 6.84 |
| EPS (Diluted) | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| Weighted Avg Shares | 1.26B | 1.26B | 1.25B | 1.25B | 1.24B |
| Weighted Avg Shares (Diluted) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B |
Gilead Sciences, Inc.
NASDAQ:GILD
Intrinsic Alpha fair value
Locked
Current Price
$168.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.